- Home
- / ASKA Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ASKA Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
¥52.5 B
FY, 2020
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| JPY | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
| Revenue | 48.9B | 46.7B | 52.5B |
| Cost of goods sold | 27.7B | 25.3B | 24.9B |
| Gross profit | 21.2B | 21.4B | 27.7B |
| Gross profit margin, % | 43.3% | 45.8% | 52.7% |
| Operating expense total | 16.1B | 17.1B | 22.5B |
| Depreciation and amortization | 2.3B | 2.5B | 4.0B |
| EBITDA | 5.1B | 4.3B | 5.2B |
| EBITDA margin, % | 10.5% | 9.2% | 9.9% |
| EBIT | 2.7B | 1.3B | 652.0M |
| EBIT margin, % | 5.4% | 2.9% | 1.2% |
| Interest expense | 14.0M | 41.0M | 64.0M |
| Pre tax profit | 3.1B | 1.9B | 901.0M |
| Income tax expense | 675.0M | 139.0M | 252.0M |
| Net Income | 2.4B | 1.7B | 649.0M |